Navigation Links
Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
Date:1/29/2008

Results from two separate Phase 1 studies show sobetirome, a selective

thyroid hormone receptor beta agonist, reduced levels of low-density

lipoprotein versus placebo

ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company developing compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced results from two Phase 1 clinical studies with its novel lipid lowering compound, sobetirome (formerly QRX-431), in development for the treatment of elevated LDL cholesterol (also known as "bad cholesterol") levels. The results of the studies indicated LDL lowering with both single and multiple doses of sobetirome in a healthy volunteer population not enriched for elevated LDL levels. Sobetirome was generally well tolerated in both studies. Sobetirome is a new selective thyroid hormone receptor beta agonist that may activate reverse cholesterol transport.

"We are excited and extremely encouraged by these Phase 1 results indicating that sobetirome was generally well tolerated and showed lowering of LDL levels. We look forward to replicating these results in larger Phase 2 and 3 trials. We believe this new compound has potential as monotherapy or in combination with statins for the many patients who are unable to tolerate current therapies or who fail to achieve lipid treatment goals with statins alone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx.

Study Results

Lipid-lowering effects in both single and multiple doses were seen in the randomized, double-blind, placebo-controlled Phase 1 studies of sobetirome. In the single dose study of 32 subjects, low-density lipoprotein (LDL) cholesterol levels decreased by up to 22% in subjects receiving up to 450 micrograms of sobetirome, compared to 2% in subjects who received placebo. The greatest reductions were observed 72 hours after dosing. In
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
5. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
6. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
7. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
10. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
11. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The Pittcon marketing department is pleased to announce ... app, Pittcon 2015 . The ... for iOS and Android devices and the Kindle Fire, ... after the event. It acts as an all-inclusive real-time ... Conferee Networking sessions and short courses. , The Pittcon ...
(Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il ... occasione di Hi Europe 2014 (dal 2 al 4 ... tratta della curcumina con la maggiore biodisponibilità di sempre, ... ingredienti approvati dalle norme europee. La curcumina ... curcumina ( Curcuma longa ) che è stata associata ...
(Date:11/24/2014)... WASHINGTON , Nov. 24, 2014  Last ... G.K. Butterfield (D-NC) took a bold ... diseases by introducing the OPEN Act. Original co-sponsors ... Hastings (D-FL). The Act will incentivize drug makers ... life-threatening rare diseases and pediatric cancers, which opens ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... (Wednesday, Sept. 1, 2010) - A new "smart ... developed by University of Waterloo engineering researchers promises ... as medical devices, microelectromechanical systems (MEMS), printers, hard ... The breakthrough technology will provide engineers with much ...
... 1 TriMark Publications, LLC ( http://www.trimarkpublications.com ), a ... publishing, cites in its newly published Regenerative Medicine ... medicine products will exceed $3 billion in 2010 and ... medicine is a technique to treat injuries and diseases ...
... 1, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:New process promises to revolutionize manufacturing of products 2Regenerative Medicine Market Expected to Reach $4.5 Billion by 2014 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6
(Date:11/18/2014)... WASHINGTON , Nov. 18, 2014  The ... Security Industry Association today jointly announce the formation ... and release of its Identity and Biometric ... (Framework). The Framework received official support from BORDERPOL, ... governments to improve and provide expertise regarding border ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... a researcher from the Tropical Research Institute of Portugal had ... a staple food crop for half of humanity ... shunned by consumers worldwide. She realised she could not do ... collaboration to address a looming threat to world,s rice supplies. ...
... March 17, 2010 -- University of Miami (UM) Rosenstiel School ... developed a new tool to monitor coral reef vital signs. ... how climate change and other ecological threats impact coral reef ... a March 2009 experiment at Cayo Enrique Reef in Puerto ...
... A dendritic cell vaccine personalized for each individual based on ... those with a deadly form of brain cancer called glioblastoma, ... has found. Published this week ... study also identified a subset of patients more likely to ...
Cached Biology News:Chemical-free pest management cuts rice waste 2Chemical-free pest management cuts rice waste 3Study provides new tool to monitor coral reef 'vital signs' 2Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer 2Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer 3
The BioLogic Maximizer mixer is for use with the Maximizer valve system. The mixer improves gradient quality by mixing the output of the BioLogic DuoFlow workstation pumps....
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
... maximum performance on minimum space. Thanks to ... heating and cooling rates have been achieved ... a maximum capacity of 48 x 0.2ml ... of much more expensive 96 well instruments. ...
... Super Sensitive Polymer-HRP IHC ... novel product based on ... technology. This system yields ... noise ratio and minimizes ...
Biology Products: